Exogenous surfactant therapy in newborn infants

Area of Science:

• Neonatology
• Pulmonology
• Biochemistry

Background:

• Neonatal Respiratory Distress Syndrome (RDS) is a significant cause of morbidity and mortality in preterm infants.
• Exogenous surfactant therapy is a cornerstone in managing RDS, aiming to improve lung function.

Purpose of the Study:

• To summarize the current evidence on the efficacy and safety of exogenous surfactant therapy for neonatal RDS.
• To compare natural versus synthetic surfactants and evaluate different administration strategies.

Main Methods:

• Systematic review and evidence synthesis of clinical trials on exogenous surfactant therapy.
• Analysis of outcomes including pneumothorax, mortality, pulmonary interstitial emphysema, and chronic lung disease.

Main Results:

• Surfactant therapy reduces pneumothorax by 30-65% and mortality by up to 40% in neonatal RDS.
• Natural surfactants show advantages over synthetic ones, with lower pneumothorax and mortality rates.
• Prophylactic administration, especially in infants <30 weeks gestation, is superior to rescue treatment, decreasing risks of pneumothorax, pulmonary interstitial emphysema, and mortality.

Conclusions:

• Exogenous surfactant therapy is highly effective and safe for neonatal RDS, with reassuring long-term follow-up.
• Prophylactic or early selective surfactant administration and multi-dose regimens are recommended for optimal outcomes.
• Further research is needed to explore surfactant therapy's role in other neonatal respiratory disorders.